Docket No. ARS.126 Serial No. 10/573,369

## In the Claims

1-44 (canceled).

- 45 (new). A DNA construct comprising a polynucleotide sequence encoding an immunoglobulin signal peptide (IgSP) fused to a tissue-type plasminogen activator (tPA) propeptide to form an IgSP-tPA pre-propeptide.
- 46 (new). The DNA construct of claim 45, wherein said immunoglobulin signal peptide is a murine immunoglobulin signal peptide.
- $\label{eq:proposed} 47 \ (\text{new}). \qquad \text{The DNA construct of claim 46, wherein said murine immunoglobulin signal peptide comprises SEQ ID NO: 3.}$
- 48 (new). The DNA construct of claim 45, wherein said tPA propeptide is a human tPA propeptide, the carboxyl-terminal extremity of said tPA propeptide consisting of amino acids Arg-Xaa-Arg-Arg.
- 49 (new). The DNA construct of claim 48, wherein said tPA propeptide consists of amino acids 23 to 32 of SEQ ID NO: 2.
- 51 (new). The DNA construct of claim 45, wherein said construct comprises SEQ ID NO: 3 fused to a nucleic acid encoding amino acids 23 to 32 of SEO ID NO: 2.

- 52 (new). The DNA construct of claim 45, wherein said DNA construct or said construct comprises SEQ ID NO: 3 fused to SEQ ID NO: 1.
- 53 (new). The DNA construct of claim 45, wherein said DNA construct encodes a fusion polypeptide comprising said IgSP-tPA pre-propeptide fused to a polypeptide of interest.
  - 54 (new). A vector comprising a DNA construct according to claim 45.
- An isolated host cell transformed with the DNA construct according to claim
  - 56 (new). The host cell of claim 55, wherein said cell is a CHO cell.
- 57 (new). A process for the production of a polypeptide of interest comprising the transfecting a host cell with a DNA construct of claim 53 and culturing the cell under conditions that allow for the production of said polypeptide of interest.
- 58 (new). The process of claim 57, further comprising isolating the polypeptide of interest from said host cells.